Literature DB >> 15750206

Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells.

A E Greijer1, M C de Jong, G L Scheffer, A Shvarts, P J van Diest, E van der Wall.   

Abstract

Hypoxia has clinically been associated with resistance to chemotherapy. The aim of this study was to investigate whether hypoxia induces resistance to doxorubicin and mitoxantrone, two common drugs in cancer treatment, in MCF-7 breast cancer cells, and SW1573 non-small lung cancer cells. In addition, the role of drug transporters P-gp, BCRP and MRP1 was analysed. Hypoxia induced resistance in MCF-7 cells to mitoxantrone shifted the IC(50) value from 0.09 microM (+/-0.01) to 0.54 microM (+/-0.06) under hypoxia, whereas survival of MCF-7 and SW1573 cells in the presence of doxorubicin was not altered. Accumulation of mitoxantrone and daunorubicin, a doxorubicin fluorescent homologue, appeared to be 5.3 and 3.2 times lower in MCF-7 cells, respectively. Cytotoxicity assays showed no increased functionality of the drug transporters P-gp, BCRP and MRP1 under hypoxia. In addition, protein levels of these drug transporters were not changed. Medium of the MCF-7 cells became more acidic under hypoxia thereby causing a decreased uptake of mitoxantrone. Hypoxia induces mitoxantrone resistance in MCF-7 cells not mediated by the three major MDR transporters. Hypoxia-induced acidification may cause this resistance by decreased cellular uptake together with a lowered cytotoxicity due to pH-dependent topoisomerase type II activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750206      PMCID: PMC4617579          DOI: 10.1155/2005/236045

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  20 in total

1.  A theoretical quantitative model for evolution of cancer chemotherapy resistance.

Authors:  Ariosto S Silva; Robert A Gatenby
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

2.  Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management.

Authors:  Laura M S Seeber; Ronald P Zweemer; René H M Verheijen; Paul J van Diest
Journal:  Obstet Gynecol Int       Date:  2010-02-14

3.  Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma.

Authors:  Laura M S Seeber; Nicole Horrée; Petra van der Groep; Elsken van der Wall; René H M Verheijen; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-06-19       Impact factor: 4.430

4.  Adaptive therapy.

Authors:  Robert A Gatenby; Ariosto S Silva; Robert J Gillies; B Roy Frieden
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

5.  Prediction of drug response in breast cancer using integrative experimental/computational modeling.

Authors:  Hermann B Frieboes; Mary E Edgerton; John P Fruehauf; Felicity R A J Rose; Lisa K Worrall; Robert A Gatenby; Mauro Ferrari; Vittorio Cristini
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

6.  Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT.

Authors:  Conor L Evans; Adnan O Abu-Yousif; Yong Jin Park; Oliver J Klein; Jonathan P Celli; Imran Rizvi; Xiang Zheng; Tayyaba Hasan
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

7.  Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1α expression.

Authors:  Agon Hyseni; Petra van der Groep; Elsken van der Wall; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2011-07-06       Impact factor: 6.730

8.  Anti-proliferation and anti-invasion effects of diosgenin on gastric cancer BGC-823 cells with HIF-1α shRNAs.

Authors:  Zhu-Jun Mao; Qian-Jue Tang; Ci-An Zhang; Zhi-Feng Qin; Bin Pang; Pin-Kang Wei; Bo Liu; Yuan-Neng Chou
Journal:  Int J Mol Sci       Date:  2012-05-24       Impact factor: 6.208

Review 9.  Targeting cellular metabolism to improve cancer therapeutics.

Authors:  Y Zhao; E B Butler; M Tan
Journal:  Cell Death Dis       Date:  2013-03-07       Impact factor: 8.469

10.  Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer.

Authors:  Guus M Bol; Venu Raman; Petra van der Groep; Jeroen F Vermeulen; Arvind H Patel; Elsken van der Wall; Paul J van Diest
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.